Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with methods enabling correct heavy-chain association usi...
Saved in:
Main Authors: | Marlena Surowka (Author), Wolfgang Schaefer (Author), Christian Klein (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024) -
Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024) -
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats
by: Andreas V. Madsen, et al.
Published: (2023) -
Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018) -
Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017)